Skip to main content
Premium Trial:

Request an Annual Quote

AGT Merger with ChemGenex Finalized

NEW YORK, June 21 (GenomeWeb News) - AGT Biosciences of Melbourne, Australia, and ChemGenex Therapeutics of Menlo Park, Calif., today announced that their merger had become final.

 

AGT Biosciences, which lists Merck-Sante as a major shareholder, has issued 28 million shares of common stock to acquire all of the issued shares of privately held ChemGenex, the companies said when the merger was announced in late April. Further financial details were not disclosed.

 

The combined entity will do business as ChemGenex Pharmaceuticals, and will trade on the Australian Stock Exchange.  Dennis Brown, CEO of ChemGenex, will serve as president of the combined firm. Brown co-founded Matrix Pharmaceutical, which was acquired by Chiron in 2002.

 

ChemGenex has two drug development programs entering or in Phase II development: Ceflatonin, a leukemia drug, and Quinamed, a compound in development for the treatment of solid tumors, for which the company is using genotyping to determine the most effective dose. The company presented on the results of a Phase I trial of Quinamed June 8 at the American Society of Clinical Oncologists meeting, and is now conducting a phase II trial to use genotyping for tumors of colon, breast, and prostate. (For more information on this trial, see the article in Pharmacogenomics Reporter 6/17/04.)

 

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.